Epoxycosatrienoic acids enhance embryonic haematopoiesis and adult marrow engraftment

Pulin Li1,2,*, Jamie L. Lahvíc1,*, Vera Binder1,3,*, Emily K. Pugach1, Elizabeth B. Riley1, Owen J. Tamplin1, Dipak Panigrahy4, Teresa V. Bowman1, Francesca G. Barrett1, Garrett C. Heffner1, Shannon McKinney–Freeman1, Thorsten M. Schlaeger3, George Q. Daley1, Darryl C. Zeldin6 & Leonard I. Zon1,2

Haematopoietic stem and progenitor cell (HSPC) transplant is a widely used treatment for life-threatening conditions such as leukaemia; however, the molecular mechanisms regulating HSPC engraftment of the recipient niche remain incompletely understood. Here we develop a competitive HSPC transplant method in adult zebrafish, using in vivo imaging as a non-invasive readout. We use this system to conduct a chemical screen, and identify epoxycosatrienoic acids (EETs) as a family of lipids1,2 that enhance HSPC engraftment. The pro-haematopoietic effects of EETs were conserved in the developing zebrafish embryo, where 11,12-EET promoted HSPC specification by activating a unique activator protein 1 (AP-1) and runx1 transcription program autonomous to the haemogenic endothelium. This effect required the activation of the phosphatidylinositol-3-0H kinase (PI(3)K) pathway, specifically PI(3)Kγ. In adult HSPCs, 11,12-EET induced transcriptional programs, including AP-1 activation, which modulate cellular processes, such as migration, to promote engraftment. Furthermore, we demonstrate that the EET effects on enhancing HSPC homing and engraftment are conserved in mammals. Our study establishes a new method to explore the molecular mechanisms of HSPC engraftment, and discovers a previously unrecognized, evolutionarily conserved pathway regulating multiple haematopoietic generation and regeneration processes. EETs may have clinical application in marrow or cord blood transplantation.

To our knowledge, a screen-based forward-genetic approach to understand transplantation biology has never been attempted. In an effort to quantify HSPC activity, we developed a competitive transplantation system in a transparent mutant zebrasih, casper5, which allows direct visualization of engraftment in vivo. We co-injected whole kidney marrow (WKM) cells from two ubiquitous GFP and DsRed2 transgenic donors into casper (Fig. 1a), and calculated relative engraftment as the ratio of GFP/DsRed2 intensity (G/R) within the same kidney region (Fig. 1b). We validated the quantitative potential of this imaging-based approach by comparing with flow cytometry-based analysis of WKM from the same recipient (Fig. 1c). The assay was also sensitive to changes in the relative number of green-to-red donor cells (Fig. 1d). Additionally, our system successfully detected the effects of sensitive to changes in the relative number of green-to-red donor cells analysis of WKM from the same recipient (Fig. 1c). The assay was also

Figure 1 | Zebrafish whole kidney marrow competitive transplantation-based chemical screen identifies EETs as enhancers of marrow engraftment.

a. Schematic of zebrafish whole kidney marrow (WKM) competitive transplantation. b. Calculation of relative engraftment capability (G/R). White dashed line denotes kidney. GKid/RKid, kidney fluorescence intensity; Gbkg/Rbkg, background fluorescence intensity. c. The G/R ratios from imaging linearly correlated with flow cytometry analysis of the same recipients (linear regression). wpt, weeks post-transplant. d, Serial dilution competitive transplantation with varying donor GFP/DsRed2 ratios. e, Four-hour transient chemical treatment increased WKM engraftment. 11,12- and 14,15-EET, 0.5 μM. Unpaired two-tailed t-test; mean and s.e.m. (d, e).

1* These authors contributed equally to this work.
A gene expression study previously reported mouse Cyp2j6, a cytochrome P450 epoxidehase, as one of the 93 genes enriched in long-term haematopoietic stem cells6.

Despite years of research on the potent of EETs in numerous physiological processes9–13, knowledge about their direct target(s) and downstream pathway(s) is still very limited. To tackle this problem, a robust system allowing easy genetic perturbation is crucial. As adult regeneration often reactivates pathways important for development, we decided to probe the effects of EETs on haematopoiesis during embryo development. Analogous to mammalian development, zebrafish HSPCs form from a flk1+ population, named haemogenic endothelium, at 24 hours post fertilization (hpf), and become runx1+ at 36 hpf in the evolutionarily conserved aorta–gonad–mesonephros (AGM) region10–12. HSPCs enter the circulation after they emerge from the haemogenic endothelium, at 24 hours post fertilization (hpf), and become haematopoietic stem cells13.

We confirmed this AGM phenotype with 11,12-EET might be inducing a conserved transcriptional programme. By contrast, runx1 induction required at least 4 h of 11,12-EET treatment and was completely blocked by cycloheximide (Extended Data Fig. 4c). Therefore, we proposed that EET-induced AP-1 expression is necessary for increasing runx1 transcription.

To test this hypothesis genetically, we globally knocked down AP-1 with anti-sense morpholinos targeting junb and junbl, which blocked runx1 expression without affecting endothelial cells of the AGM (Extended Data Fig. 5), suggesting that AP-1 might be required for HSPC specification from haemogenic endothelium. To test whether AP-1 function is autonomous to the haemogenic endothelium, we delivered a dominant-negative form of JunB protein (dnUNB) specifically to the flk1+ endothelial cells, before the induction of runx1, to functionally inhibit all AP-1 activity. Although flk1:dnUNB did not significantly reduce the expression of runx1 in AGM-treated embryos, it suppressed the EET-induced increase of runx1 in the AGM (Fig. 3a, b). Combined with the gene expression data, these genetic analyses showed that 11,12-EET activates an AP-1 and runx1 transcriptional cascade of cell-fate specification autonomous to the haemogenic endothelium.

In an effort to define downstream signalling events for 11,12-EET, we performed a chemical suppressor screen in zebrafish embryos by examining the capability of various chemicals to suppress the 11,12-EET-induced AP-1 and runx1 gene signature (Fig. 3c). Several PI(3)K inhibitors completely blocked the signature without detrimental effects to overall embryonic development (Fig. 3d, e and Extended Data Fig. 6a). To interrogate specific PI(3)K catalytic subunits, we assayed subunit-specific chemical inhibitors and morpholinos targeting individual class I PI(3)K subunits. Among α- , β- , γ- and δ-subunits of PI(3)K, only PI(3)Kα loss of function specifically abrogated the runx1 induction in the AGM and tail non-haematopoietic tissue (Extended Data Fig. 6b, c). Furthermore, 11,12-EET enhanced PI(3)K activity in immortalized human umbilical vein endothelial cells, assayed by Akt phosphorylation (data not shown). No such increase was seen in human umbilical cord blood CD34+ HSPCs, although EET-induced gene expression changes could be partially blocked in these cells by co-treatment with PI(3)K inhibitors. This indicates PI(3)K functions either directly downstream of 11,12-EET or as a parallel pathway, depending on the cellular context. In either case, PI(3)K activity is required for inducing the AP-1 and runx1 transcription cascade in the AGM.

To understand how 11,12-EET treatment leads to increased engraftment in already-specified HSPCs, we performed RNA-sequencing in human umbilical cord blood CD34+ HSPCs and a human myeloid cell line (U937), and used Ingenuity Pathway Analysis (IPA) to decipher the biological pathways regulated by 11,12-EET in both cell types.

Figure 2 | 11,12-EET enhances HSPC specification in the zebrafish embryo AGM. a, Schematic of HSPC development in zebrafish embryos. b, Representative images of whole-mount in situ hybridization showing 11,12-EET (24–36 hpf treatment) induced HSPC marker runxl in the AGM and a tail non-haematopoietic tissue (>8 independent experiments, n > 100). c, d, 11,12-EET (24–46 hpf) enhanced CD41:GFP/flk1:DsRed2 double-positive HSPCs (white arrowheads) emerging in the AGM. Arrows indicate blood flow. e, f, Same treatment increased the number of HSPCs in the CHT. e, Representative montage images of Runxl+23:GFP HSPCs (white arrowheads) engraving CHT. f, Representative montage images of Runxl+23:GFP HSPCs in the CHT. g, h, Enhanced CD34+ HSPCs in the CHT. i, j, Representative montage images of Runxl+23:GFP HSPCs (white arrowheads) engraving CHT. j, k, Representative montage images of Runxl+23:GFP HSPCs in the CHT. l, Unpaired two-tailed t-test, mean and s.e.m. (d, e).
11,12-EET induces a PI3K-dependent AP-1//Jun transcriptional program to increase HSPC specification. a, b, Stable flk1:dnJUNB-2A-GFP expression blocking AP-1 function suppressed 11,12-EET-enhanced HSPC in the AGM. Representative images of runx1 and cmyb in situ hybridization (a) and quantification (b) after 11,12-EET treatment (24–36 hpf). Embryos scored as high, medium or low runx1 and cmyb, summed across 4 experiments. *p = 0.01, ***p < 0.0001, Chi-square. NC, not significant; WT, wild-type. c, Schematic of chemical screen for EET signalling pathway suppressors. d, e, 11,12-EET induced AP-1 family transcription factors (fos2, junb and junbl) (d) and runx1 (e), suppressed by cotreatment with the PI3K inhibitor LY294002 (LY) in the AGM and tail (d, e) (three independent experiments, n > 40). Same images from Fig. 2b were used as staining controls (e).

These data show that besides promoting HSPC specification from the haemogenic endothelium, 11,12-EET can also directly induce gene expression programs beneficial for engraftment in already-specified HSPCs. Similarly, 11,12-EET treatment of zebrafish embryos after 48 hpf, when AGM HSPC production has already completed, leads to increased HSPCs in the CHT in a PI3K-dependent manner, without affecting cell apoptosis or proliferation (Extended Data Fig. 8). Our data strongly suggest that 11,12-EET modulates cell migration and cell–cell interaction during HSPC engraftment.

To test the evolutionary conservation of EET-induced haematopoietic phenotypes, we examined the effect of 11,12-EET on HSPC engraftment in mammalian bone marrow competitive transplantation. Consistently, 11,12-EET promoted greater short-term chimaerism by 4 weeks post-transplant compared to control-treated cells (Fig. 4a, b). Even up to 24 weeks, EET-treated marrow maintained greater multi-lineage contribution (Fig. 4c). Enhanced short- and long-term engraftment suggests that 11,12-EET may affect both stem and progenitor cells, perhaps by establishing a competitive advantage at the early stage of engraftment. In a whole-bone-marrow (WBM) homing assay, we found 11,12-EET promoted the initial seeding of progenitor cells in the bone marrow (Fig. 4d, e). The early effect could be due to an enhanced cell migration and cell–cell signalling program, since assaying cell proliferation or apoptosis in whole marrow immediately after 11,12-EET treatment did not show significant changes (Extended Data Fig. 9). However, this does not exclude the possibility of a later onset of anti-apoptotic effects on transplantation. Finally we found transient inhibition of PI3K partially blocked EET-induced enhancement of long-term, multi-lineage engraftment after mouse transplantation.
bone marrow transplant (Fig. 4f). Thus, the EET effect on enhancing HSPC engraftment is evolutionarily conserved in fish and mammals.

Our unbiased chemical genetic studies establish a new eicosanoid pathway for haematopoiesis, which increases HSPC specification in the AGM by inducing AP-1 and runx1, and also enhances HSPC engraftment by modulating several biological pathways, such as migration and cell–cell signalling. Previous work in our laboratory discovered a different eicosanoid, PGE2, could also enhance marrow engraftment13. Both PGE2 and EETs are arachidonic-acid-derived eicosanoids that are locally produced near wounds, and may facilitate progenitor recruitment, engraftment and proliferation. Despite their common origin, the underlying molecular signalling mechanisms and activities of PGE2 and EETs are different (Supplementary Table 5). Previously, we showed that PGE2 signals through the cAMP-dependent Gα2 subunits21. Previously, we showed that PGE2 signals through the cAMP-dependent Gαs-coupled PGE2 receptor for its pro-haematopoietic effects3. Using chemical inhibition and genetic loss-of-function approaches, we screened all families of zebrafish Gx subunits. Notably, we found that gna12 and gna13 are specifically required for EET-induced AP-1 and runx1 expression (Extended Data Fig. 10). Inhibiting GxTs did not suppress the EET phenotypes, indicating that EETs and PGE2 have different signalling mechanisms.

During marrow transplantation, the achieved chimaerism over time is critical, and the time to adequate neutrophil engraftment is an important milestone for treatment success. In addition to improving long-term repopulation, EETs seem to have a prominent effect on progenitor engraftment, as shown by increased chimaerism early after transplantation. Our studies highlight the importance of lipid mediators in regulating HSPC engraftment, and the manipulation of these pathways could have clinical impact for patients undergoing transplantation.

Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.

Received 31 October 2012; accepted 11 May 2015.

1. Specter, A. A. & Kim, H.-Y. Y. Cytochrome P450 epoxygenase pathway of polyunsaturated fatty acid metabolism. Biochim. Biophys. Acta 1851, 356–365 (2015).
2. Noda, K. et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285, 1276–1279 (1999).
3. White, R. M. et al. Transparent adult zebrafish as a tool for in vivo transplantation analysis. Cell Stem Cell 2, 183–189 (2008).
4. North, T. E. et al. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature 447, 1007–1011 (2007).
5. Goessling, W. et al. Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell 136, 1136–1147 (2009).
6. Forsberg, E. C. et al. Molecular signatures of quiescent, mobilized and leukemia-initiating hematopoietic stem cells. PLoS ONE 5, e8785 (2010).
7. Panigrahy, D., Greene, E. R., Pozzi, A., Wang, D. W. & Zeldin, D. C. EET signalling in cancer. Cancer Metastasis Rev. 30, 525–540 (2011).
8. Pfister, S. L., Gauthier, K. M. & Campbell, W. B. Vascular pharmacology of epoxygenase polyunsaturated fatty acids. Adv. Pharmacol. 60, 27–59 (2010).
9. Wang, Y. et al. Arachidonic acid epoxygenase metabolites stimulate endothelial cell growth and angiogenesis via mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways. J. Pharmacol. Exp. Ther. 314, 522–532 (2005).
10. Lam, E. Y., Hall, C. J., Crosier, P. S., Crosier, K. E. & Flores, M. V. Live imaging of Runx1 expression in the dorsal aorta tracks the emergence of blood progenitors from endothelial cells. Blood 116, 909–914 (2010).
11. Bertrand, J. Y. et al. Haematopoietic stem cells derive directly from aortic endothelium during development. Nature 464, 108–111 (2010).
12. Kissa, K. & Herbomel, P. Blood stem cells emerge from aortic endothelium by a novel type of cell transition. Nature 464, 112–115 (2010).
13. Boisset, J. C. et al. In vivo imaging of haematopoietic cells emerging from the mouse aortic endothelium. Nature 464, 116–120 (2010).
14. Murayama, E. et al. Tracing hematopoietic precursor migration to successive hematopoietic organs during zebrafish development. Immunity 25, 963–975 (2006).
15. Tamplin, O. J. et al. Haematopoietic stem cell arrival triggers dynamic remodeling of the perivascular niche. Cell 160, 241–252 (2015).
16. Renaud, S. J., Kubota, K., Rumi, M. A. & Soares, M. J. The FOS transcription factor family differentially controls trophoblast migration and invasion. J. Biol. Chem. 289, 5029–5039 (2014).
17. Qiu, D. et al. PRSS5-containing protein phosphatase 2A complexes promote cancer cell migration and invasion through regulation of AP-1 transcriptional activity. Oncogene 34, 1333–1339 (2015).
18. Chen, M. J., Yokomizo, T., Zeigler, B. M., Dzierzak, E. & Speck, N. A. Runx1 is required for the endothelial to haematopoietic cell transition but not thereafter. Nature 457, 887–891 (2009).
19. Chen, Y., Falck, J. R., Manthali, V. L., Jat, J. L. & Campbell, W. B. 20-iodo-14,15-epoxyeicos-9(Z)-enoyl-3-azidophenylsulfonamide: photoaffinity labeling of a 14,15-epoxyeicosatrienoic acid receptor. Biochemistry 50, 3840–3848 (2011).
20. Yang, W. et al. Characterization of epoxygenase-derived epoxyeicosatrienoic acid binding site in U937 membranes using a novel radiolabeled agonist, 20-125-14,15-epoxyeicos-9(Z)-enoyl acid. J. Pharmacol. Exp. Ther. 324, 1019–1027 (2008).
21. Lappano, R. & Maggiorini, M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nature Rev. Drug Discov. 10, 47–60 (2011).
22. Fromel, T. et al. Soluble epoxide hydrolase regulates hematopoietic progenitor cell function via generation of fatty acid diols. Proc. Natl Acad. Sci. USA 109, 9995–10000 (2012).

Supplementary Information is available in the online version of the paper.

Acknowledgements We thank C. R. Lee, M. L. Edin and N. Gray for providing reagents; Y. Zhou, A. Dibiase, S. Yang, S. Datta, P. Manos, R. Mathieu and M. Ammerman for technical assistance; H. Huang for providing graphic illustration; R. M. White, T. E. North and C. Mosimann for discussion. Microarray studies were performed by the National Genetics Core Facility at Boston Children’s Hospital, supported by NIH-P50-NS040828 and NIH-PO1-GM06555. S. Li in Y. Zhang’s laboratory at the Longwood HHMI joint core facility helped with RNA-seq, Li2G, and Q.D. are Howard Hughes Medical Institute (HHMI) investigators. This work was supported by HHMI and National Institutes of Health (NIH) grants R01 HL04880, P015PO1HL32262-32, 5P30 DK49216, 5R01 DK53298, SU01 HL10001-05, R24 DK092760, and 1R01HL097794-04 (to L.I.Z.). This work was also funded, in part, by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences (Z01 ES025034 to D.C.Z.), the National Cancer Institute grant R01CA148633-01A5 (D.P.), and DFG and Care-for-Rare Foundation (V.B.).

Author Contributions P.L. and L.I.Z. designed the study, analysed data and wrote the manuscript, with help from J.L.L. and V.B. P.L. developed the zebrafish competitive transplantation and performed the chemical screen with technical help from E.K.P. L.L. performed the mouse experiments with technical help from T.V.B., S.M. and G.C.H. P.L. performed the zebrafish microarray and embryo chemical/genetic suppressor screens with technical help from E.B.R. J.L.L. performed zebrafish embryo genetic studies and AGM timelapse imaging. V.B. performed RNA-seq and analysis on human cells with technical help from F.G.B. O.J.T. performed CHI time-lapse imaging. T.M.S. provided the chemical library, D.P. and D.C.Z. offered reagents and information related to the EET study. All authors discussed the results and commented on the manuscript.

Author Information The gene expression profiling data have been deposited in the Gene Expression Omnibus (GEO) under the accession code GSE66767. Reprints and permissions information is available at www.nature.com/reprints. The authors declare competing financial interests: details are available in the online version of the paper. Readers are welcome to comment on the online version of the paper. Correspondence and requests for materials should be addressed to L.I.Z. (zon@enders.tch.harvard.edu).
Zebrafish strains. Zebrafish were maintained in accordance with Animal Research Guidelines at Boston Children’s Hospital (BCH). The following transgenic zebrafish were used in this study: Tg(β-actin:GFP)39, casper5, RedGlo (ubiquitous DsRed2 transgenic)40, Tg(flk1:dsRed2)31, Tg(CD41:GFP)41, Tg(Runx1+23mCherry)30, and Tg(Runx1+23sGFP)30. The + 23 enhancer region of mouse Runx1 was used to drive HSPC-specific expression27. Tg(flk1:dsUNJB- 2A-GFP) was constructed by cloning a human JUNB into a to2 transgenesis vector27.

Chemical treatment. The ICCB Known Bioactive Library was purchased from BIOMOL (Enzo Life Sciences) and used for the adult zebrafish transplantation-based chemical screen. Chemicals were diluted at 1:2000 ratio. Chemicals used for the secondary round of screening for confirmation were from a different aliquot of the library, independent of the primary screen plate. 11,12-EET (Cayman Chemical, 50511) was resuspended in DMSO with original organic solvent evaporated. AS605240 (Sigma-Aldrich A0233) was resuspended in DMSO. The following chemicals were used for zebrafish marrow treatment: dimPGE2 (Cayman, 14750), 10 μM; BIO (EMD), 0.5 μM, 0.5 μM 11,12-EET and 14,15-EET were used for zebrafish WKM treatment (Fig. 1e); 2 μM 11,12-EET for all mouse WBM treatment (Fig. 4); and 5 μM 11,12-EET for all zebrafish embryo treatment (Figs 2 and 3). The concentrations were chosen based on dose titration pilot experiments. Selected doses spanned 0.1 to 50 μM. For the chemical suppressor screen, the suppressors were added 30 min before 11,12-EET. Zebrafish embryos were incubated with inhibitors at different concentrations. The highest effective concentrations tested without causing general toxicity are listed in Supplementary Table 1.

Adult zebrafish kidney marrow transplantation and chemical screen. Adult zebrafish transplantation-based chemical screen was done at the human embryonic stem cell core at BCH. Three-month-old casper recipients (both male and female) received split-dose irradiation of 15 Gy each two days and one day before transplantation. Adult zebrafish kidney marrow cells from multiple donors were dissected, pooled together, processed into single-cell suspension and injected into irradiated AGM. The number of recipients per treatment condition in the chemical screen, recipients were randomly assigned to each treatment group. 20,000 CD45.1 WBM cells from age- and gender-matched B6L6 mouse donors were treated in DMEM plus 2% FBS at room temperature for 4 h with 2 μM 11,12-EET. For the suppressor experiment (Fig. 4f), 10 μM LY294002 was added to the cells 30 min before the addition of 11,12-EET. Chemicals were washed off before cells were resuspended in PBS and mixed with 200,000 fresh CD45.2 mouse WBM cells. Donor cells were retro-orbitally injected into CD45.2 recipients. Each treatment condition included 10 recipients per experiment. The 12-week survival rate in each experiment was 90–95%, and recipients that died before 12 weeks were excluded from the analysis.

Mouse bone marrow transplant. All mice were maintained in accordance with JACUC approved protocols in accordance with BCH animal research guidelines. Nine-week-old CD45.1 and CD45.2 (C57BL/6) male mice were purchased from Jackson Laboratories and housed for 2–3 weeks before the experiments. All CD45.2 recipients received an 11 Gy split dose of γ-irradiation before transplantation, and were randomly assigned to each treatment group. 20,000 CD45.1 WBM cells from age- and gender-matched B6L6 donors were treated in DMEM plus 2% FBS at room temperature for 4 h with 2 μM 11,12-EET. For the suppressor experiment (Fig. 4f), 10 μM LY294002 was added to the cells 30 min before the addition of 11,12-EET. Chemicals were washed off before cells were resuspended in PBS and mixed with 200,000 fresh CD45.2 mouse WBM cells. Donor cells were retro-orbitally injected into CD45.2 recipients. Each treatment condition included 10 recipients per experiment. The 12-week survival rate in each experiment was 90–95%, and recipients that died before 12 weeks were excluded from the analysis.

Mouse peripheral blood chimaerism analysis. Peripheral blood was stained with lineage-specific antibodies and analysed on LSRII (BD Biosciences) to assess engraftment. The following antibodies were used: Gr1 (RB6-8C5), Mac1 (M1/ 70), B220 (RA3-B2), CD3 (145-2C11) and Ter119 from eBioscience; CD45.1 and CD45.2 from BD Biosciences. The CD45.1 chimaeras in non-irradiated, untransplanted CD45.2 mice were used as a negative staining control. Recipients with multi-lineage chimaerism above the average negative-control chimaerism plus 3 standard deviations were considered to have multi-lineage engraftment (Fig. 40).

Mouse competitive homing assay. The mouse competitive homing experiment was performed as described, with modifications51. In brief, CD45.1 mouse WBM were treated with either DMSO or 2 μM 11,12-EET at room temperature for 3.5 h at a density of 2 × 106 cells per ml. DiO dye was added to the cell suspension (1:200) and incubated at 37 °C for 30 min. At the same time, WBM from CD45.2 mice were incubated at room temperature for 3.5 h without chemical treatment, then labelled with Diodide dye (1:200) at 37 °C for 30 min. After the incubation and labelling, the chemicals and dyes were washed off. The Diodide-labelled CD45.1 bone marrow cells (DiO labelled CD45.1) and Diodide-labelled CD45.2 bone marrow cells (DiD labelled CD45.2) were mixed competitively transplanted into CD45.2 recipients (2.5 × 106 from each donor). Recipients received total body irradiation of 11 Gy one day before transplantation. 16 h after transplant, the recipients were euthanized and bone marrow was analysed by flow cytometry for both Diodide/Diodide and surface lineage markers (Gr1, Mac1, B220, CD3, Ter119, from Ebioscience) and C-kit (2B8, BD Biosciences). The ratio between the percentages of Diodide+ (donor) and Diodide− (competitor) cells within different cell populations was quantified. DiO and DiD are from Vybrant Multicolor Cell- Labelling Kit (Molecular Probes, V-22899).

Mouse bone marrow apoptosis and proliferation assays. For apoptosis analysis, WBM cells were treated with DMSO or 2 μM 11,12-EET for 4 h in vitro and stained using the AnnexinV apoptosis kit (BD Biosciences), together with antibodies against lineage markers, Sca-1 (E13-161.7) and C-kit (2B8). The 7-AAD / annexinV+ cells are the apoptotic population. For proliferation analysis, mouse WBM were treated with DMSO or 2 μM 11,12-EET for 4 h in vitro, in the presence of 5-methyl-2′-deoxyuridine (5-aza) to inhibit DNA synthesis.
of 10 μM BrdU, then fixed, permeabilized and stained with anti-BrdU antibody (BD Pharmingen BrdU Flow Kits)33, together with antibodies against lineage markers, Sca-1 and c-Kit.

**Gene expression profiling and IPA analysis.** Gene expression profiling data are available in GEO (accession numbers GSE39707 and GSE66767). For the zebrafish embryo gene expression study, total RNA was extracted from 36 hpf zebrafish embryos treated with DMSO or 5 μM 11,12-EET between 24 and 36 hpf, with three biological replicates each and n = 25 in each group. Microarray hybridization was performed with the Affymetrix GeneChip Zebrafish Genome Array. Hybridized microarray was background-corrected, normalized and multipletested using Goldenspike (http://www2.ccr.buffalo.edu/halfon/spike/) in R/Bioconductor4. Genes with q < 0.1 by SNR test were considered differentially expressed (Supplementary Table 3). For RNAseq analysis on human cells, total RNA was extracted from treated CD34+ and U937 cells with the RNeasy mini plus kit from Qiagen. After quality control on the Bioanalyzer (Agilent), total RNA was depleted of ribosomal RNA with the RiboZero gold kit (Epicentre). Enriched mRNA was applied to library preparation according to manufacturer’s protocol (NEBNext Ultra). After repeated quality control for average DNA input size of 300 base pairs (bp), samples were sequenced on a HiSeq Illumina sequencer with 2 × 100-bp paired-end reads. Quality control of RNA-Seq data sets was performed by FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and Cutadapt36 to remove adaptor sequences and low quality regions. The high-quality reads were aligned to UCSC build hg19 of the human genome using TopHat 2.0.11 without novel splicing form calls37. Transcript abundance and differential expression were calculated with Cufflinks 2.2.1 (ref. 37). FPKM values were used to normalize and quantify each transcript. log2(FC) (log2 fold change), P and q values were calculated. As the experiment was not performed in biological replicates, the P and q values were not taken into consideration for further analysis of the data. Results are listed with a cutoff of log2(FC) > 0.5 for upregulated genes and log2(FC) < −0.5 for downregulated genes in Supplementary Table 4. Analysis of overlapping upregulated genes in both cell types after EET treatment was done using Venny (http://bioinfogp.cnb.csic.es/tools/venny/index.html). The list of overlapping genes was analysed using IPA (QIAGEN) to map enriched bio-functions.

**Statistics.** The comparison of multi-lineage engraftment in Fig. 4b and f were done by two-tailed Fisher’s exact test by comparing the engrafted versus non-engrafted recipients. Using the mean chimaera plus 2× s.e.m. in the DMSO control group as the cutoff, recipients with a chimaerism higher than the cutoff were considered engrafted (Fig. 4b). Embryos in the in situ hybridization experiments were scored blindly and analysed by Chi-square tests or two-tailed Fisher’s exact test in the case of small sample sizes. The rest of the statistics were done with unpaired two-tailed t-test. Graphs show mean with s.e.m. No statistical methods were used to predetermine sample size. All the zebrafish embryos, adult zebrafish and mice for transplantation were randomized into each treatment group.

23. Traver, D. et al. Transplantation and in vivo imaging of multilineage engraftment in zebrafish bloodless mutants. Nature Immunol. 4, 1238–1246 (2003).
24.Blake, A., Crockett, R., Essner, J., Hackett, P. & Nasevicius, A. Reombinant constructs and transgenic fluorescent ornamental fish therefrom. US patent US7,700,825 B2 (2010).
25.Kikuchi, K. et al. Retinoic acid production by endocardium and epicardium is an injury response essential for zebrafish heart regeneration. Dev. Cell 20, 397–404 (2011).
26.Ma, D., Zhang, J., Lin, H. F., Italiano, J. & Handin, R. I. The identification and characterization of zebrafish hematopoietic stem cells. Blood 118, 289–297 (2011).
27.Bee, T. et al. The mouse Runx1 +/− hematopoietic stem cell enhancer confers hematopoietic specificity to both Runx1 promoters. Blood 113, 5121–5124 (2009).
28.Ikebe, D., Wang, B., Suzuki, H. & Kato, M. Suppression of keratinocyte stratification by a dominant negative JunB mutant without blocking cell proliferation. Genes Cells 12, 197–207 (2007).
29.Pugach, E. K., Li, P., White, R. & Zon, L. Retro-orbital injection in adult zebrafish. J. Vis. Exp. 34, 1645 (2009).
30.Slusarski, D. C., Corees, V. G. & Moon, R. T. Interaction of Wnt and a Frizzled homologue triggers G-protein-linked phosphatidylinositol signalling. Nature 390, 410–413 (1997).
31.Sundstrom, C. & Nilsson, K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int. J. Cancer 17, 565–577 (1976).
32.Lam, B. S., Cunninghamham, C. & Adams, G. B. Pharmacologic modulation of the calcium-sensing receptor enhances hematopoietic stem cell lodgment in the adult bone marrow. Blood 117, 1167–1175 (2011).
33.Challen, G. A., Boles, N., Lin, K. K. & Goodell, M. A. Mouse hematopoietic stem cell identification and analysis. Cytometry A 75, 14–24 (2009).
34.Choe, S. E., Boutros, M., Michelson, A. M., Church, G. M. & Halfon, M. S. Preferred analysis methods for Affymetrix GeneChips revealed by a wholly defined control dataset. Genome Biol. 6, R16 (2005).
35.Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBO J. 17, 1 (2011).
36.Trpanjetic, C., Pachter, L. & Salzberg, S. L. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105–1111 (2009).
37.Trpanjetic, C. et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nature Biotechnol. 28, 511–515 (2010).
38.Lee, C. R. et al. Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. FASEB J. 24, 3770–3781 (2010).
Extended Data Figure 1 | Zebrafish WKM competitive transplantation-based chemical screen identifies EETs as enhancers of marrow engraftment. 

a, WKM from Tg(β-actin:GFP) donors were dissected, dissociated as single-cell suspension, and incubated with chemicals at room temperature for 4 h in a round-bottom 96-well plate. Meanwhile, WKM were dissected from RedGlo zebrafish, counted and kept on ice. After the drug treatment, chemicals were washed off and cells were resuspended in 0.93 PBS plus 5% FBS. Approximately 20,000 treated green WKM and 80,000 untreated red WKM were co-injected retro-orbitally into sublethally irradiated casper zebrafish (n = 10 per chemical). For every independent screening day, negative control (DMSO) and positive control (10 μM dmPGE2) treatments were used for normalization and quality assurance. The engraftment was measured at 4 wpt by fluorescence imaging and ImageJ quantification as described in Fig. 1b.

b, EET metabolic pathway: arachidonic acid is released by phospholipase A2 (PLA2) from the membrane lipid bilayer. EETs are synthesized directly from arachidonic acid by the cytochrome P450 family of epoxygenases, especially 2C and 2J in human38, and get degraded by soluble epoxide hydrolase (sEH), generating dihydroxyeicosatrienoic acids (DiHET). Four isomers of EET exist in vivo: 5,6-, 8,9-, 11,12- and 14,15-EET.
Extended Data Figure 2 | 11,12-EET enhances HSPC specification in the AGM in zebrafish embryos. Tg(CD41:GFP/flk1:DsRed2) embryos were treated with DMSO or 5 μM 11,12-EET starting at 24 hpf, then mounted for spinning disc confocal timelapse imaging from 30–46 hpf in the presence of the chemicals. Data are mean and s.e.m., unpaired two-tailed t-tests, n = 10 for DMSO, n = 7 for EET. a, More HSPCs are directly specified in EET-treated AGM. Graph shows HSPCs born by direct specification/budding only, excluding cells born by division of an already-budding cell. b, c, 11,12-EET does not influence the rate of HSPC division in the AGM, shown by per movie, percentage of budding HSPCs that divide at least once (b) and divide twice or more (c) before leaving the AGM or before the end of timelapse recording.
Extended Data Figure 3 | 11,12-EET treatment between 24 and 48 hpf increases the number of HSPCs in the CHT. 

a, Embryos were treated between 24 and 48 hpf with either DMSO or 5 μM 11,12-EET. Chemicals were washed off at 48 hpf, and embryos grew in drug-free environment for another 24 h. 

b, 11,12-EET treatment increased the number of mCherry^+ HSPCs in the CHT in Tg(Runx1^+23:mCherry) embryos (see also Fig. 2e). Representative images of the CHT from the two groups. 

c, The same chemical treatment increased the staining of cmyb, a HSPC marker, by whole-mount RNA in situ hybridization. Representative images from each group (a total of n > 60 from three independent experiments).
Extended Data Figure 4 | EET signalling pathway activates AP-1 family members as primary transcriptional targets, and runx1 as a secondary transcriptional target. 

**a**, Wild-type embryos were incubated with 300 μM cycloheximide, a translation blocker, for 30 min before the addition of 5 μM 11,12-EET at 24 hpf. Embryos were fixed for in situ hybridization at 25 hpf or 28 hpf. **b**, AP-1 transcription was induced after 1 h treatment with 11,12-EET, insensitive to cycloheximide inhibition. This means AP-1 induction does not depend on de novo protein synthesis, indicating AP-1 members are primary transcriptional targets of the EET signalling pathway. **c**, runx1 transcription was induced after 4 h treatment with EET (two columns on the left) and cycloheximide completely blocked EET-induced runx1 expression (two columns on the right). This suggests runx1 transcription depends on de novo protein synthesis of an upstream factor(s) upon EET stimulation, indicating that runx1 is a secondary transcriptional target of the EET signalling pathway. Representative images from each group (a total of n > 30 from two independent experiments).
Extended Data Figure 5 | Knocking down junb and junbl inhibits HSPC specification in the AGM. a, Wild-type embryos were injected with antisense morpholinos at the one-cell stage, and treated with DMSO or 5 μM 11,12-EET starting from 24 hpf. Embryos were fixed at 36 hpf for in situ hybridization of runx1. b, Knocking down junb completely blocked runx1 expression at 36 hpf both in the AGM and the tail non-haematopoietic tissue (middle row). By contrast, knocking down c-jun did not block the increase of runx1 (bottom row), consistent with the lack of c-jun upregulation in EET-treated embryos (data not shown). c, junb morphants still developed normal vascular structure in the AGM at 28 hpf, as shown by endothelial marker flk1. Representative images from each group (a total of n > 40 from three independent experiments).
Extended Data Figure 6 | PI(3)K\(\gamma\) activation is specifically required for EET-induced gene expression signature. a, Similar to LY294002 (Fig. 3d–e), another pan-PI(3)K/AKT inhibitor, wortmannin (1 \(\mu\)M), blocked EET-induced \textit{runx1} expression both in the AGM and tail. Representative images from each group (a total of \(n > 60\) from three independent experiments). b, Morpholinos specific to PI(3)K\(\gamma\), but not \(\alpha\), \(\beta\) and \(\delta\) subunits (data not shown), prevented EET-induced \textit{runx1} in the AGM and tail. Embryos were injected at 1–2-cell stage with the indicated amount of morpholino and treated with DMSO or 5 \(\mu\)M 11,12-EET from 24–36 hpf. \textit{In situ} hybridization for \textit{runx1} performed at 36 hpf and percentages of embryos having high, medium or low expression in the AGM and present or absent expression in the tail are shown. Graph summarizes three experiments, \(n \approx 10\) embryos for each condition (0, 1 and 2 \(\mu\)g, data are mean and s.e.m.) or one experiment \(n \approx 9\) for all conditions (4 and 6 \(\mu\)g). c, The PI(3)K\(\gamma\)-specific inhibitor AS605240 (AS6) recapitulates the morpholino phenotype. Embryos treated from 24 to 36 hpf with DMSO or 5 \(\mu\)M 11,12-EET, with or without 0.3–1.0 \(\mu\)M AS6, then fixed and stained for \textit{runx1} at 36 hpf. DMSO, \(n = 23\); EET, \(n = 33\); EET+0.3 \(\mu\)M AS6, \(n = 35\); EET+1.0 \(\mu\)M AS6, \(n = 38\). *\(P < 0.05\), ***\(P < 0.001\), two-tailed Fisher’s exact test.
Extended Data Figure 7 | 11,12-EET upregulates genes involved in cell-to-cell signalling and cellular movement in haematopoietic progenitors.

a, Venn diagram showing a common set of 54 genes upregulated (log₂(fc) > 0.5) after 2 h of 11,12-EET treatment (5 μM), both in human myeloid U937 cells and human umbilical cord CD34+ HSPCs (see also Supplementary Table 4 for lists of up- and downregulated genes).

b, Ingenuity Pathway Analysis (IPA) of the overlapping gene set between the two cell types for enrichment of bio-functions. Biological processes, such as cell-to-cell signalling and cellular movement, were highly enriched, supporting the capability of EETs in enhancing engraftment (see also Supplementary Table 4 for a comprehensive list of all biological functions predicted to be activated or suppressed based on the same gene set).

c, Activation of recruitment of blood cells is caused by upregulation of chemokines and cytokines such as CXCL8 and OSM after EET treatment, as well as by upregulation of transcription factors, such as AP-1 genes (FOS). Orange dashed arrows depict activation. Shades of red represent the level of activation. Numbers underneath factors show RNaseq FPKM (fragments per kilobase of exon per million reads mapped) values in U937 cells.
Extended Data Figure 8 | 11,12-EET treatment after HSPC specification still enhances the number of HSPCs in the CHT. a, Embryos were treated with DMSO or 5 μM 11,12-EET between 48 and 72 hpf to bypass the HSPC specification process in the AGM. 72-hpf embryos were fixed and tested on the following assays. b, In situ hybridization for cmyb, a marker for HSPCs. EET treatment significantly increased the staining, while LY294002, a pan-PI(3)K inhibitor, suppressed the effect. Representative images from each group (a total of \( n = 60 \) from four independent experiments). c, A PI(3)Kγ-specific inhibitor AS605240 (AS6) also blocked the EET-induced increase of cmyb staining. Percentage of embryos having high, medium or low expression in the CHT is shown. \( n \approx 11 \) for all conditions. Chi-square analysis. d, The increase of HSPCs in the CHT is not due to effects on proliferation. Immunofluorescence staining for phospho-histone H3 (pH3) as a marker for proliferating cells. The number of pH3-positive cells was manually counted. Two-tailed \( t \)-test showed no significant difference between DMSO- versus EET-treated embryos. \( n = 9 \) for DMSO, \( n = 10 \) for EET. e, TUNEL staining as an assay for apoptotic cells. Apoptosis was minimal in the CHT at 72 hpf. As a staining control, obvious apoptosis was detected in the same embryos in the brain region, and was comparable between DMSO- and EET-treated embryos (data not shown).
Extended Data Figure 9 | 11,12-EET treatment of mouse WBM does not lead to immediate changes in cell proliferation or apoptosis. 

**a. In vitro apoptosis assay on WBM treated with DMSO or 2 μM 11,12-EET for 4 h.** The 7-AAD-negative and annexinV-positive population are the cells undergoing apoptosis. No significant differences between the two groups were observed either in Lin^−^Sca^−^Kit^+^ or Lin^−^Sca^−^Kit^+^ progenitor populations (n = 4 each), mean and s.e.m.

**b, c. In vitro proliferation assay on WBM treated with DMSO or 2 μM 11,12-EET for 4 h, in the presence of 10 μM BrdU.** No significant differences between the two groups were observed either in Lin^−^Sca^−^Kit^+^ (b) or Lin^−^Sca^−^Kit^+^ populations (c) for any cell cycle stage. Unpaired two-tailed t-test, n = 4 each, bar denotes the mean. D, DMSO; E, EET.
**Extended Data Figure 10** | Ga12/13 is specifically required for EET-induced phenotypes in zebrafish embryos. All embryos were treated with DMSO or 5 μM 11,12-EET between 24 and 36 hpf. Chemical inhibitors were added 30 min before EET. mRNA or morpholinos (MO) were injected at the one-cell stage. a, b, Inhibiting Gαs or Gzα had no effect on EET-induced runx1 expression. Embryos were categorized into two groups with either normal or increased runx1 expression level (n > 20 each). PtxA, pertussis toxin A, 3 pg, inhibiting Gzα (ref. 30); H89, 5 μM, PKA inhibitor downstream of Gαs5; SQ, SQ22536, 50 μM, adenylate cyclase inhibitor downstream of Gαs5. Representative images from each group (b) (a total of n > 40 from two independent experiments). c–f, Synergistic effects of gna12/13a/13b knockdown on suppressing runx1 expression. Knocking down gna13a/b or gna12 alone partially inhibited EET-induced runx1 expression in the AGM and tail (c). gna12 MO: 2 ng; gna13a/13b MOs: 1 ng each. Triple morpholinos against gna12, gna13a and gna13b (0.67 ng each) completely blocked EET-induced multiple gene expression, including runx1, genes in regeneration (fosl2) and cholesterol metabolism (hmgcs1) (d), while other major tissue development processes were not significantly affected, such as notochord (shh), muscle (myoD), and blood vessels (flk, ephrinB2) (e). f, The results were quantified. Embryos were categorized as having decreased, normal or increased runx1 expression. The bar graph represents the percentage of embryos in each group (n > 30).